| Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals | 
| Synonyms [18F]FP-R01-MG-F2 | 
| Target | 
| Action antagonists | 
| Mechanism αvβ6 antagonists(Integrin alpha-V/beta-6 antagonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseEarly Phase 1 | 
| First Approval Date- | 
| Regulation- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Cholangitis, Sclerosing | Phase 1 | United States  | 08 Nov 2017 | |
| Cholangitis, Sclerosing | Phase 1 | United States  | 08 Nov 2017 | |
| COVID-19 | Phase 1 | United States  | 08 Nov 2017 | |
| COVID-19 | Phase 1 | United States  | 08 Nov 2017 | |
| Idiopathic Pulmonary Fibrosis | Phase 1 | United States  | 08 Nov 2017 | |
| Idiopathic Pulmonary Fibrosis | Phase 1 | United States  | 08 Nov 2017 | |
| Pancreatic Cancer | Phase 1 | United States  | 12 Jan 2016 | 





